enVVeno Medical Corporati...

NASDAQ: HJLI · Real-Time Price · USD
10.38
-0.21 (-1.98%)
At close: Oct 01, 2021, 6:00 AM

Company Description

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease.

The company is headquartered in Irvine, California and currently employs 9 full-time employees.

The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD).

The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease.

The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices.

The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

enVVeno Medical Corporation
enVVeno Medical Corporation logo
Country United States
IPO Date May 31, 2018
Industry Medical - Devices
Sector Healthcare
Employees 19
CEO Robert A. Berman

Contact Details

Address:
70 Doppler
Irvine, California
United States
Website http://www.hancockjaffe.com

Stock Details

Ticker Symbol HJLI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661053
CUSIP Number 41015N106
ISIN Number US41015N1063
Employer ID 33-0936180
SIC Code 3841

Key Executives

No executives data available.

Latest SEC Filings

Date Type Title
Jul 31, 2025 10-Q Quarterly Report
May 20, 2025 4 Filing
May 20, 2025 3 Filing
May 20, 2025 8-K Current Report
Apr 30, 2025 10-Q Quarterly Report
Apr 21, 2025 8-K Current Report
Mar 12, 2025 S-8 Filing
Mar 12, 2025 S-3/A [Amend] Filing
Feb 28, 2025 S-3 Filing
Feb 28, 2025 10-K/A [Amend] Annual Report